Jean Paul Thiery

Nov 1, 2024 | jitc.bmj.com | Mingyu Liu |Deping Han |Jean Paul Thiery |Xi Zhang

Regular and Young Investigator Award AbstractsCellular Therapies 467 Engineered chimeric antigen receptor-expressing TILs for liver cancer treatment using a novel MSE-TIL platform Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Dec 14, 2023 | nature.com | Yuta Adachi |Nicola J Armstrong |Stephanie Claire Bridgeman |Tuan Zea Tan |Jean Paul Thiery |Hiromichi Ebi | +1 more

AbstractDespite the promising antitumor activity of SHP2 inhibitors in RAS-dependent tumours, overall responses have been limited by their narrow therapeutic window. Like with all MAPK pathway inhibitors, this is likely the result of compensatory pathway activation mechanisms. However, the underlying mechanisms of resistance to SHP2 inhibition remain unknown. The E3 ligase SMURF2 limits TGFβ activity by ubiquitinating and targeting the TGFβ receptor for proteosome degradation.